I welcome the Bill.
I welcome its emphasis on improving research—I have already touched on drug development—and the provisions to facilitate clinical trials, because the grim reality is that for glioblastoma, those trials are hard to conduct.
There are too few patients, and frequently their life expectancy is too limited.
Anything that can be done to connect eligible patients with researchers faster and with less friction is valuable.